BioSpace News Archive

TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today reported financial results and provided a business update for the third quarter ended September 30, 2022.

Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced positive clinical data for TRV045, its selective sphingosine-1-phosphate subtype 1 (S1P1) receptor modulator.

SCYNEXIS, Inc. today reported financial results for the third quarter ended on September 30, 2022.

LumiraDx Limited today announced operational and financial results for the third quarter ended September 30, 2022.

Kernal Biologics, Inc. today announced it will have three presentations at the International mRNA Health Conference being held in Boston and virtually from November 8th to 10th, 2022.

PolyPid Ltd., a late-stage biopharma company aiming to improve surgical outcomes, provided a corporate update and reported financial results for the three and nine months ended September 30, 2022.

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will participate in a fireside chat at the Jefferies London Healthcare Conference on November 16, 2022, at 10:20 a.m. GMT.

Kazia Therapeutics Limited today announced that final data from its phase II study of paxalisib in patients with newly diagnosed glioblastoma will be the subject of an oral presentation at the upcoming annual meeting of the Society for Neuro-Oncology (SNO), which will be held from 17-20 November in Tampa, FL.

Bristol Myers Squibb (NYSE: BMY) today announced that the company will take part in a fireside chat at the Wolfe Research Healthcare Conference on Wednesday, November 16, 2022 in New York City.

Surmodics, Inc. today reported financial results for its fourth quarter and fiscal year ended September 30, 2022, and introduced its financial outlook for the fiscal year ending September 30, 2023.